CRSP - CRISPR Therapeutics AG

56.5
-0.830   -1.469%

Share volume: 1,167,922
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.17%

PREVIOUS CLOSE
CHG
CHG%
$57.33
-0.83
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 5%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.03%
1 Month
13.68%
3 Months
-1.50%
6 Months
4.44%
1 Year
24.09%
2 Year
-28.81%
Key data
Stock price
$56.50
P/E Ratio 
0.00
DAY RANGE
$54.80 - $57.04
EPS 
-$6.47
52 WEEK RANGE
$30.04 - $78.48
52 WEEK CHANGE
$30.36
MARKET CAP 
4.998 B
YIELD 
N/A
SHARES OUTSTANDING 
95.985 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-04-2025
BETA 
1.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,657,346
AVERAGE 30 VOLUME 
$1,608,918
Company detail
CEO: Samarth Kulkarni
Region: US
Website: crisprtx.com
Employees: 460
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.

Recent news